Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Wyatt

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 4, 2018
Diversity-oriented synthesis of bicyclic fragments containing privileged azinesNicola Luise, Paul G Wyatt
Chemistry (Weinheim an Der Bergstrasse, Germany)|May 8, 2018
Generation of Polar Semi-Saturated Bicyclic Pyrazoles for Fragment-Based Drug-Discovery CampaignsNicola Luise, Paul G Wyatt
Acta Crystallographica. Section F, Structural Biology Communications|May 7, 2015
Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferaseDavid A Robinson, Paul G Wyatt
Journal of Computer-Aided Molecular Design|August 30, 2021
Ligand binding: evaluating the contribution of the water molecules network using the Fragment Molecular Orbital methodIva Lukac, Paul G Wyatt, Ian H Gilbert, et al.
Current Topics in Medicinal Chemistry|March 16, 2011
Target validation: linking target and chemical properties to desired product profilePaul G Wyatt, Ian H Gilbert, Kevin D Read, et al.
Trends in Parasitology|October 27, 2007
Target assessment for antiparasitic drug discoveryJulie A Frearson, Paul G Wyatt, Ian H Gilbert, et al.
Journal of Medicinal Chemistry|September 9, 2014
The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasisRobert Urich, Raffaella Grimaldi, Torsten Luksch, et al.
The Journal of Biological Chemistry|January 8, 2011
Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolismJanine König, Susan Wyllie, Geoffrey Wells, et al.
ACS Medicinal Chemistry Letters|November 16, 2023
Correction to "Bespoke Drug Discovery Training for Low-Middle Income Countries"Lauren A Webster, Susan J Farrell, Ian H Gilbert, et al.
Drug Discovery Today|November 8, 2016
Fragment library design, synthesis and expansion: nurturing a synthesis and training platformPeter C Ray, Michael Kiczun, Margaret Huggett, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|December 4, 2018
Diversity-oriented synthesis of bicyclic fragments containing privileged azinesNicola Luise, Paul G Wyatt
Chemistry (Weinheim an Der Bergstrasse, Germany)|May 8, 2018
Generation of Polar Semi-Saturated Bicyclic Pyrazoles for Fragment-Based Drug-Discovery CampaignsNicola Luise, Paul G Wyatt
Acta Crystallographica. Section F, Structural Biology Communications|May 7, 2015
Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferaseDavid A Robinson, Paul G Wyatt
Journal of Computer-Aided Molecular Design|August 30, 2021
Ligand binding: evaluating the contribution of the water molecules network using the Fragment Molecular Orbital methodIva Lukac, Paul G Wyatt, Ian H Gilbert, et al.
Current Topics in Medicinal Chemistry|March 16, 2011
Target validation: linking target and chemical properties to desired product profilePaul G Wyatt, Ian H Gilbert, Kevin D Read, et al.
Trends in Parasitology|October 27, 2007
Target assessment for antiparasitic drug discoveryJulie A Frearson, Paul G Wyatt, Ian H Gilbert, et al.
Journal of Medicinal Chemistry|September 9, 2014
The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasisRobert Urich, Raffaella Grimaldi, Torsten Luksch, et al.
The Journal of Biological Chemistry|January 8, 2011
Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolismJanine König, Susan Wyllie, Geoffrey Wells, et al.
ACS Medicinal Chemistry Letters|November 16, 2023
Correction to "Bespoke Drug Discovery Training for Low-Middle Income Countries"Lauren A Webster, Susan J Farrell, Ian H Gilbert, et al.
Drug Discovery Today|November 8, 2016
Fragment library design, synthesis and expansion: nurturing a synthesis and training platformPeter C Ray, Michael Kiczun, Margaret Huggett, et al.
Pageof 9